National University of Malaysia

ukm.my

Total trials

113

Active

33

Phase 3

5

Total enrollment

13,316

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
CD19 CAR-T CELLS2
Cyclophosphamide1
Fludarabine1
CAR-T cells1
Gentamicin - single dose1
Distilled water1
Silver diamine fluoride- potassium iodide1
Fluoride varnish1
Intrapleural t-PA/Dnase arm1
t-PA (Alteplase) 5-10mg and Tyloxapol 200mg1
Heparin saline lock1
Hydroxychloroquine Oral1
Syrup Prospan1
N-Acetylcysteine1
Autologous dentin graft1
Xenograft1

Next readouts

  • 2025-06-02
  • 2026-06-01
  • 2026-07-08
  • 2026-08-31
  • 2026-11-30
  • 2027-01-18
  • 2027-03-01
  • 2027-11-30
  • 2028-06-01
  • 2028-12-02

Top conditions

  • Pleural Effusion3
  • Gestational Diabetes3
  • Chronic Obstructive Pulmonary Disease2
  • Pleural Infection2
  • Trigger Finger2
  • Type 2 Diabetes2
  • Endophthalmitis Postoperative2
  • Anxiety2

Frequently asked questions about National University of Malaysia

How many clinical trials does National University of Malaysia have on ClinicalTrials.gov?
National University of Malaysia is listed as the lead sponsor on 113 clinical trials in ClinicalTrials.gov, 33 of which are currently active (recruiting, enrolling, or ongoing).
How many of National University of Malaysia's trials are in Phase 3?
5 of National University of Malaysia's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does National University of Malaysia focus on?
National University of Malaysia's most-studied conditions on ClinicalTrials.gov are Pleural Effusion, Gestational Diabetes, Chronic Obstructive Pulmonary Disease, Pleural Infection, Trigger Finger.
When are National University of Malaysia's next clinical trial readouts?
National University of Malaysia has 10 upcoming primary-completion readouts tracked here; the soonest is “To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)”, expected around 2025-06-02.